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Laryngeal squamous-cell carcinoma is often preceded by
pre-malignant lesions. In this study, pre-malignant as well as
malignant laryngeal lesions were analyzed using p53 immu-
nohistochemistry and in situ hybridization for chromosomes
1, 7, 9, 17 and 18. Microsatellite analysis was performed on
laser-microdissected tissue fragments with the aim of study-
ing loss of heterozygosity (LOH) of 9p21, 17p13 and 18q21.
Sequential biopsies were analyzed from a few cases to study
genetic progression in more detail. The following genetic
progression patterns were observed: (i) histologically normal
mucosa and hyperplastic lesions without malignant progres-
sion were typically disomic for all chromosomes tested and
showed no or only basal cell layer positivity for p53 and no
allelic loss; (ii) hyperplastic lesions preceding dysplastic/inva-
sive growth frequently showed trisomy for chromosome 7
and LOH of 9p21 and 17p13, and small foci within these
lesions sometimes showed tetraploidization and p53 positiv-
ity; (iii) dysplastic lesions were characterized by a tetraploid
chromosome content, LOH of 9p21 and 17p13 and p53 pos-
itivity; (iv) carcinoma in situ lesions and invasive laryngeal
carcinomas showed a more unbalanced chromosome pat-
tern and an additional 18q21 LOH. These results show that
different steps in aneuploidization correlate with LOH of
9p21, 17p13 and 18q21 in early laryngeal carcinogenesis.
These genomic changes could be of potential use in the
diagnosis and prognosis of pre-malignant laryngeal lesions.
© 2001 Wiley-Liss, Inc.
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Head-and-neck squamous-cell carcinomas (HNSCC) often ex-
hibit an aneuploid DNA content; loss of chromosomal regions
3p14-21, 9p21, 17p13 and 18q21; mutations in the p53 gene; and
amplifications of the CCND1 proto-oncogene.1–4 Many of these
genetic alterations take place in pre-malignant stages of the dis-
ease, and some appear to be indicators of malignant transforma-
tion.5–7 Although the timing of the different genetic changes in
malignant transformation is gradually being resolved, little is
known about the correlation between the different genetic changes.
At present, e.g., it is unclear whether loss of heterozygosity (LOH)
of 9p21 and/or 17p13 occurs before, simultaneously with or after
the aneuploidization process in early stages of head-and-neck
carcinogenesis.
In this study, a series of pre-malignant laryngeal lesions were
screened by in situ hybridization (ISH) using centromeric probes
for chromosomes 1, 7, 9, 17 and 18 to investigate the presence and
the pattern of chromosomal abnormalities in the different parts of
these lesions. Selection of DNA probes was based on previous ISH
studies on HNSCC.8,9 In addition, p53 immunohistochemistry was
performed on these lesions since there are strong indications that
alterations in this tumor-suppressor gene may lead to overall
genetic instability.10–12 Based on ISH data, laser-facilitated micro-
dissection was used to isolate small pre-malignant regions with a
specific chromosomal content, followed by a fluorescent microsat-
ellite analysis using markers for 9p21, 17p13 and 18q21. The
choice of these loci was based on a detailed allelotype of HNSCC
published by Field et al.2 and on an LOH study by Califano et al.,5
using pre-malignant lesions of the head and neck. This approach
allowed us to draw conclusions (i) on the type and extent of
genetic alterations present in different stages of laryngeal carcino-
genesis, (ii) on the correlation between the process of aneu-
ploidization and the loss of specific chromosomal regions and (iii)
on the role of p53 in the progression of the disease.
MATERIAL AND METHODS
Patient material
Formalin-fixed, paraffin-embedded biopsy specimens were
available from 27 (pre-)malignant laryngeal lesions of 18 patients.
From all specimens, a series of 4-mm-thick sections was used for
detailed histological examination, ISH, laser-facilitated microdis-
section and p53 immunohistochemistry. One section was stained
with hematoxylin and eosin and reviewed by an experienced
pathologist (FJB). Normal mucosa, hyperplasia, dysplasia, carci-
noma in situ (CIS) or carcinoma areas were identified and the
specific areas marked on the slide for detailed comparisons with
the genetic data.
ISH
ISH was performed and evaluated essentially as described previ-
ously.7,13 Briefly, after deparaffinization, sections were pre-treated
with 85% formic acid containing 0.3% H2O2, followed by incubation
at 80°C in 1 M sodium thiocyanate. After digestion with pepsin from
porcine stomach mucosa (800 to 1,200 U/mg protein; Sigma, St.
Louis, MO) at a concentration of 4 mg/ml in 0.02 N HCl, individual
sections were hybridized using centromere-specific probes for human
chromosomes 1, 7, 9, 17 or 18,14 all labeled with biotin-11-dUTP
(Boehringer-Mannheim, Mannheim, Germany). Immunocytochemi-
cal detection was performed by a standard avidin-biotin complex
procedure. Signals were developed using diaminobenzidine/H2O2;
sections were counterstained with hematoxylin and mounted in En-
tellan (Merck, Darmstadt, Germany).
Based on the ISH results, lesions were classified as either
disomic, trisomic, tetrasomic or polysomic according to the max-
imum chromosome copy number present in the lesion (2, 3, 4 or
.4, respectively).
Laser-facilitated microdissection
Laser-facilitated microdissection was performed essentially as
described previously,15 with minor adaptations. Briefly, 4-mm-
thick sections were mounted onto 0.17 mm glass slides, deparaf-
finized and stained with hematoxylin and eosin. The UV laser
microbeam used for microdissection (Palm, Wolfratshausen, Ger-
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many) consisted of a pulsed nitrogen laser coupled through the
fluorescence illumination path of the microscope. Unwanted cells
and areas of surrounding tissue were brought into the laser beam
using a motorized, computer-controlled microscope stage and
eliminated by the high photon density within the laser focus. In this
way, a tissue-free gap around the area of interest was created, and
this area (often consisting of 1,000 or more cells) was collected
manually under a stereomicroscope using a sterile syringe needle.
Cells were transferred to a 1.5 ml microcentrifuge tube and could
be stored for months at room temperature. Areas were selected for
microdissection based on the histological classification and ISH
results of each specimen. These areas were microdissected from 3
to 5 serial sections. As a source for normal DNA, stromal cells and
lymphocytes present in the same biopsy specimen were used.
Histologically normal mucosa showing a disomic chromosome
content (as detected by ISH) was also included in the analysis
when present adjacent to a pre-malignant lesion.
Fluorescent microsatellite analysis
Genomic DNA was extracted using the QIAamp Tissue Kit
(Qiagen, Hilden, Germany) with a slightly modified protocol.
Incubation of the tissue with proteinase K was prolonged to about
60 hr at 55°C. After column purification, the DNA was dissolved
in 30 ml of bidistilled water. PCR analysis targeted sequences
containing highly polymorphic microsatellite repeat motifs at loci
on chromosomes 9p21 (D9S161), 17p13 (TP53) and 18q21
(D18S35). These microsatellite markers were specifically chosen
because the PCR products obtained were of very small size (vary-
ing between 101 and 147 bp), which made them suitable for
amplifications from the DNA isolated from formalin-fixed and
paraffin-embedded cells. Oligonucleotides were labeled with either
6-FAM (D9S161), HEX (TP53) or TET (D18S35). PCRs were
performed according to Erber et al.,16 using 3 ml of DNA and
adding a final extension step of 30 min at 72°C. After amplifica-
tion, PCR samples were diluted 1:5 in formamide, heated to 95°C
for 2 min, chilled on ice and analyzed on an ABI PRISM 310
Genetic Analyzer (ABI Perkin-Elmer, Nieuwekerk, the Nether-
lands) with Genescan software. To estimate the degree of LOH,
i.e., the allelic loss in the heterozygously paired normal and (pre-
)malignant samples, an LOH value was calculated according to
Cawkwell et al.17 as (T1/T2)/(N1/N2). T1 and N1 are the peak
height values of the shorter allele for the (pre-)malignant and the
normal samples, respectively, and T2 and N2 are the peak height
values of the longer allele for the (pre-)malignant and normal
samples, respectively. When the allele ratio calculated by this
equation was above 1.0, the ratio was converted, using 1/[(T1/T2)/
(N1/N2)] to give a result in the range 0.0–1.0. A value at or below
0.50 was taken to indicate LOH. Microsatellite instability was
indicated by the presence of novel allele peaks in the pre-malig-
nant or malignant DNA sample analyzed for a particular micro-
satellite marker, which was not present in the corresponding nor-
mal DNA analyzed for this marker.
p53 immunohistochemistry
An immunohistochemical assessment of (mutated) p53 protein
expression was performed on 4-mm-thick paraffin sections. After
deparaffinization, sections were pre-treated with 0.3% H2O2 in
methanol to quench endogenous peroxidase activity. Antigen re-
trieval was performed by microwave heating in 0.01 M citrate
buffer (pH 6.0). Both normal and mutant p53 proteins were de-
tected using the monoclonal antibody (MAb) clone DO-7 (Dako,
Glostrup, Denmark). After incubation with the biotinylated sec-
ondary antibody, immunocytochemical detection was further per-
formed as described for ISH. In each analysis, known p53-negative
and p53-positive oropharynx tumors served as controls. The extent
of the p53 immunostaining reaction was scored visually as (I)
negative, (II) nuclear staining limited to the basal cell layer, (III)
scattered positive nuclear staining in 5% to 10% of cells or (IV)
positive nuclear staining in most cells in the lesion.
RESULTS
ISH
Histologically normal mucosa, present in 15 of the 28 biopsy
specimens, was used as internal control. Nuclei within these nor-
mal epithelia showed 0, 1 or 2 ISH signals for all chromosome
probes used, with no evidence of nuclei with more than 2 ISH
signals. Table I shows the ISH results obtained in 34 (pre-)malig-
nant lesions, which were histologically identified in the 28 speci-
mens of the 18 patients. In Figure 1a–c, examples of the ISH
results are presented. Four major chromosomal patterns were dis-
tinguished: (i) disomy for all chromosomes tested, (ii) trisomy for
chromosome 7 as the sole numerical chromosomal change, (iii)
tetrasomy for all chromosomes tested and (iv) chromosomal copy
number imbalances and polysomy in 1 or more of the chromo-
somes tested. In general, patterns (i) and (ii) were observed in
hyperplastic lesions and patterns (iii) and (iv) were observed in
dysplastic lesions, CIS and SCC.
In most cases, a homogeneous chromosomal pattern was ob-
served in a specific histological area. In 4 cases, however, small
foci of 10 to 100 nuclei containing a chromosomal pattern that
deviated from the pattern observed in the rest of the lesion were
identified. Trisomy for chromosome 7 was observed in part of the
hyperplastic lesion in case 5. Cases 6, 17 and 18 contained small
foci of nuclei with tetrasomy (and polysomy) for all chromosomes,
while the rest of the lesion showed a trisomy for chromosome 7.
Polysomy (i.e., .4 ISH signals per nucleus) was observed in
many dysplastic lesions and most of the CIS and SCC lesions,
often as a small subpopulation within a tetrasomic lesion. Poly-
somy occurred more or less randomly for chromosomes 1, 7, 17
and 18. Polysomy for chromosome 9, however, was not detected.
Imbalances in chromosomal copy numbers occurred predomi-
nantly in the group of CIS and SCC lesions and appeared to be
present throughout the lesion.
Microsatellite analysis of 9p21, 17p13 and 18q21
Laser-facilitated microdissection was performed on tissue sec-
tions stained with hematoxylin and eosin from all specimens.
Microdissection was guided by histology and ISH results, by
which tissue compartments with and without chromosomal
changes were precisely mapped (Fig. 1). DNA was isolated, and
amplification for the microsatellites D9S161 (located on 9p21),
TP53 (located on 17p13) and D18S35 (located on 18q21) was
performed. Microsatellite data for each specimen are presented in
Table I. Figure 1g–k illustrates typical LOH results. For these
microsatellites, the presence or absence of allelic loss could easily
be determined based on the LOH value; all lesions classified as
LOH contained values between 0 and 0.49, whereas all lesions
classified as presenting no LOH showed values between 0.60 and
0.98. Histopathologically normal mucosa, isolated from 15 spec-
imens, did not show allelic loss when compared to control non-
mucosal samples. Most hyperplastic lesions also showed retention
of heterozygosity, though allelic loss for 9p21 was observed in all
hyperplastic areas of case 17 and allelic loss for 17p13 was
observed in a hyperplastic region adjacent to a dysplasia in case
18. Virtually all dysplastic lesions, CIS and SCC displayed LOH
for at least 1 of the 3 loci. Allelic loss at 9p21 and 17p13 was
shown at high frequencies in both dysplastic lesions as well as CIS
and SCC. Only 1 of 6 dysplastic lesions displayed LOH of 18q21,
whereas 2 of 3 CIS and 2 SCCs revealed allelic loss at this locus.
In only 1 case (case 15) was microsatellite instability observed for
the microsatellite TP53, both in the dysplastic lesion and in the
invasive carcinoma diagnosed 4 years later (Fig. 1k).
p53 immunohistochemistry
Normal mucosa, present in 15 specimens adjacent to the (pre)-
malignant lesions, showed either no p53 staining or only faintly
positive nuclear staining in the basal cell layer. Identical results
were obtained in most hyperplastic lesions, whereas a majority of
the dysplastic lesions, CIS and SCC showed nuclear p53 staining
in the majority of cells (Table I, Fig. 1d).
194 VELTMAN ET AL.
Correlation between histology, ISH analysis, p53
immunohistochemistry and microsatellite analysis
The approach we chose allowed detailed comparison between
the genetic changes as detected by the different techniques in the
different histological stages of laryngeal carcinogenesis. Table II
illustrates the accumulation of genetic alterations with histological
progression. Table III shows the increase in LOH and p53 posi-
tivity with subsequent steps of aneuploidization as detected in
these lesions by ISH. Neither LOH nor p53 over-expression was
detected in lesions with disomy for all chromosomes. In contrast,
4 of 7 lesions with sole trisomy for chromosome 7 displayed LOH
of 9p21 and/or 17p13, and 2 of these lesions showed extensive p53
immunostaining. The percentage of lesions with LOH and p53
over-expression further increased in lesions that contained more
extensive chromosomal alterations such as tetraploidization and
chromosomal instability. LOH at 18q21 was detected only in
lesions showing chromosomal imbalances or polyploidization.
LOH at either 9p21 or 17p13 is strongly correlated with an
increased copy number (aneusomy) for the corresponding chro-
mosomes, as detected using a centromere-specific DNA probe in
the ISH. In contrast, only part of the lesions with aneusomy for
chromosome 18 showed 18q21 LOH. Immunostaining of the p53
gene (located on 17p13) was present in lesions that typically
contain multiple copies of chromosome 17 and show allelic loss of
the p53 locus.
Genetic changes correlated with progression of individual cases
In Table IV, a detailed scheme is presented of 4 cases from
which progressive lesions were available. Genetic alterations such
as allelic loss at 9p21, p53 positivity and chromosomal duplication
were shown to persist in many of the biopsy specimens from these
cases, even when the time interval between different biopsies was
1 to 4 years. In case of histological progression, additional genetic
changes, such as LOH of 18q21, arose (Fig. 1g–j). Furthermore,
the occurrence of chromosomal copy number imbalances and
polyploidization was typical in these later stages.
In 2 of the cases depicted in Table IV, genetic changes were
observed in a hyperplastic area but not in the dysplastic area
located in the same biopsy specimen. A small but clearly identified
dysplastic region of case 17 (biopsy c) did not display numerical
chromosomal alterations or p53 over-expression. Microdissection
of this dysplastic region followed by microsatellite analysis did not
reveal LOH for 9p21 (the other 2 markers were not informative).
In contrast, a small hyperplastic region present in the same biopsy
specimen contained tetrasomy for all chromosomes tested and was
p53-positive. Microsatellite analysis of this region showed clear
LOH at 9p21. In case 18 (biopsy b), a similar result was obtained
by ISH, but unfortunately, the 2 regions were too small (both
contained approx. 50 nuclei/tissue section) for PCR amplification.
DISCUSSION
In this study, histologically different stages of laryngeal carci-
nogenesis were analyzed by chromosome ISH, p53 immunohisto-
chemistry and microsatellite analysis. The ISH and immunohisto-
chemical techniques were applied directly onto tissue sections and
allowed a detailed investigation of the chromosomal content and
the p53 status in different areas present in a biopsy specimen.
Based on the results of these analyses, specific tissue compart-
ments were isolated using laser-facilitated microdissection, and a
fluorescent microsatellite analysis was performed to detect LOH of
chromosomal loci 9p21, 17p13 and 18q21. In our opinion, this
approach has several advantages over the conventional approach,
whereby regions are isolated for genetic analyses on the basis of
TABLE I – OVERVIEW OF THE HISTOLOGICAL AND GENETIC CHANGES OBSERVED IN THE LARYNGEAL BIOPSY SPECIMENS
Case Biopsy Histology ISH CH.1 ISH CH.7 ISH CH.9 ISH CH.17 ISH CH.18 P53 IHC 9p21 17p13 18q21
1 A Hyperplasia 2 2 2 2 2 — — — NI
2 A Hyperplasia 2 2 2 2 2 — — — —
3 A Hyperplasia 2 2 2 2 2 BL Pos — — —
4 A Hyperplasia 2 2 2 2 2 — — — —
5 A Hyperplasia 1 2 2 2 2 2 — — — —
Hyperplasia 2 (small focus) 2 3 2 2 2 S Pos — — —
6 A Dysplasia 1 2 3 2 2 2 — LOH — NI
Dysplasia 2 (small focus) 4 6–8 4 4 4 Pos n.e. n.e. n.e.
7 A Dysplasia 4 4 4 4 4/6–8 Pos LOH LOH NI
8 A Dysplasia 4 4 4 4/6–8 4 S Pos LOH LOH —
9 A Dysplasia 4/6–8 4/6–8 4 4/6–8 4 Pos — LOH —
10 A Dysplasia 4/6–8 4/6–8 4 4 4 S Pos LOH NI —
11 A CIS 2 3 4 4 4 Pos LOH LOH LOH
12 A Hyperplasia 2 2 2 2 3 — — — —
CIS 4 4 4 4 3/6–8 — LOH n.e. —
13 A CIS 2 4 2 4/6–8 4 S Pos — n.e. n.e.
14 A CIS 4/6–8 4/6–8 4 4 4 Pos LOH — LOH
15 A Dysplasia 2 3 n.e. n.e. n.e. Pos — MSI n.e.
B SCC 2 3 2 2 2 — LOH MSI n.e.
16 A Dysplasia 4 4 4 4 4 Pos LOH LOH —
B Dysplasia 4 4 4 4 4 Pos LOH LOH —
C SCC 4/6–8 4/6–8 4 4/6–8 2/3 Pos LOH LOH LOH
17 A Hyperplasia 2 3 2 2 2 BL Pos LOH NI NI
B Hyperplasia 2 3 2 2 n.e. — LOH NI NI
Hyperplasia (small focus) 4 4/6–8 4 4 n.e. — LOH NI NI
C Hyperplasia (small focus) 4 4 4 4 4 Pos LOH NI NI
Dysplasia (small focus) 2 2 2 2 2 — — NI NI
18 A Hyperplasia 2 2 2 2 2 BL Pos NI — —
B Hyperplasia (small focus) 3/6–8 4 4 4 4 — n.e. n.e. n.e.
Dysplasia (small focus) 2 2 2 2 2 — n.e. n.e. n.e.
C Hyperplasia 2 3 2 2 2 — NI LOH —
Dysplasia (small focus) 3 4/6–8 4 4 4 — NI LOH LOH
D SCC 4 4/6–8 2/3 4 2/3 — NI LOH LOH
E Hyperplasia 2 2 2 2 2 BL Pos NI — —
CH., chromosome; IHC, immunohistochemistry; A–E, subsequent biopsies; CIS, carcinoma in situ; 2, disomy; 3, trisomy; 4, tetrasomy; 6–8,
polysomy; 2, no expression/no LOH; BL Pos, basal cell layer-positive; S pos, scattered-positive; pos, positive; MSI, microsatellite instability,
NI, not informative; n.e., not evaluable.
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histology. Firstly, as pointed out by many authors,18 the his-
topathological features of pre-malignant lesions of the aerodiges-
tive tract are subtle and overlap with non-neoplastic reactive
processes. It does not appear logical to use the subjective morpho-
logical method as a starting point for a detailed molecular analysis
that requires the use of a pure population with a minimal amount
of non-aberrant “normal” cells. Screening the biopsy specimens by
chromosome ISH and p53 immunohistochemistry easily identifies
tissue compartments within these specimens harboring the most
altered (genetically) cell population. It is this cell population that
was our target for the microsatellite analysis and was, therefore,
isolated by laser-facilitated microdissection. Secondly, this ap-
proach allows a detailed comparison of genetic alterations during
the carcinogenic process, such as allelic loss of specific chromo-
somal regions, different steps in the aneuploidization process and
alterations in expression of the p53 tumor-suppressor gene.
Based on the results obtained in this study, a 3-step genetic
progression model for early laryngeal carcinogenesis emerges (Ta-
bles II, III): (i) the earliest detectable genetic changes appear to be
acquisition of trisomy for chromosome 7 and allelic loss at 9p21
and 17p13, and the tissue containing these genetic alterations is
typically hyperplastic; (ii) this is followed by over-expression of
the (presumably mutated) p53 gene and tetraploidization, and the
tissue containing these genetic alterations is typically mildly to
moderately dysplastic; (iii) chromosomal copy number imbalances
and polyploidization occur together with allelic loss at 18q21. The
tissue containing these genetic alterations is typically CIS or SCC.
A small proportion of laryngeal lesions remain disomic during
progression, e.g., as illustrated by case 15. In this case, microsat-
ellite instability was observed at the TP53 locus, indicating that
another form of genetic instability is present. In addition, all results
were obtained in a relatively small cohort and should be confirmed
in a larger series.
In agreement with the genetic progression model proposed by
Califano et al.,5 we observed LOH of 9p21 and 17p13 to be among
the earliest detectable genetic changes in head-and-neck carcino-
genesis. These changes appear to occur before tetraploidization, in
contrast to LOH of 18q21, which was found only in advanced
precursor lesions containing chromosomal imbalances and poly-
somy. These data suggest that LOH of 9p21 and 17p13, containing
the important cell-cycle regulators p16INK4a and p53, respectively,
may contribute to chromosomal missegregation, resulting in aneu-
ploidy. Our present results as well as of a previous study by our
group on oral precursor lesions19 indicate that p53 over-expression
indeed precedes the tetraploidization process. These data support
literature indicating that alterations in the p53 tumor-suppressor
gene lead to overall genetic instability.10–12 These genetic changes
persist within the pre-malignant epithelium for several years and,
thus, may be used in the follow-up of a given pre-neoplastic lesion.
LOH of 18q21, although not of importance in the early stages of
laryngeal carcinogenesis, is very likely of relevance in tumor
progression.20,21 Candidate tumor suppressors on this locus are the
DCC (deleted in colon cancer) and the DPC4 (deleted in pancre-
atic cancer) genes.22,23
How can LOH be explained in light of the aneuploidization
process? If a duplication of the whole chromosome 9 occurs before
allelic loss at 9p21, this loss would have to take place on 2
duplicate chromosome copies, whereas only 1 chromosome copy
has to be affected if LOH occurs before duplication. This has also
been discussed by Varella-Garcia et al.24 studying the relation
between chromosomal duplication and allelic loss in non-small-
cell lung carcinoma. Our data strongly suggest that the allelic loss
observed at 9p21 and 17p13 occurred before tetraploidization,
whereas allelic loss at 18q21 took place after tetraploidization. In
support of this hypothesis, allelic loss of 9p21 was present in the
entire dysplastic area of case 6, whereas disomy for chromosome
9 was observed in the majority of this lesion. Interestingly, in a
small focus of about 10 nuclei located within the dysplasia, chro-
mosomal duplication as well as nuclear p53 immunostaining were
FIGURE 1 – Typical examples of results obtained by ISH, p53 im-
munohistochemistry, laser-facilitated microdissection and fluorescent
microsatellite analysis. (a–f) ISH and p53 immunohistochemistry on
the biopsy specimen of case 7. Tetrasomy for chromosomes 7 (over-
view in a, detail in b) and 17 (c) is present in the dysplastic region,
which also shows p53 positivity (d). This region was microdissected
from a section stained with hematoxylin and eosin (e) by laser-
facilitated microdissection (f). Stromal cells surrounding the region
were eliminated, and the region was manually collected. (g–j) LOH
results of biopsies A (h), B (i) and C (j) of case 16 for the loci D9S161
(lane 1), TP53 (lane 2) and D18S35 (lane 3). (g) Results for normal
mucosa from this case are depicted for comparison. For reasons of
clarity, peaks representing specific alleles are marked with an asterisk;
other alleles are so-called stutter bands caused by inefficient amplifi-
cation. D9S161 shows complete loss of the second allele in both
dysplastic lesions and SCC. TP53 shows a significant reduction of the
first allele in the same lesions. Retention of heterozygosity is observed
for D18S35 in the 2 dysplastic lesions, whereas SCC displays LOH.
(k) Microsatellite instability observed for TP53 in dysplasia (lane 2) as
well as SCC (lane 3) of case 15. Scale bar 5 80 mm (a,d,e,f) and 10
mm (b,c).
TABLE II – CORRELATION BETWEEN HISTOLOGY, LOH DATA AND p53 STATUS
Histology
Chromosomal locus p53 IHC positive
staining19p21 17p13 18q21
Hyperplasia 4/112 (36) 1/10 (10) 0/8 (0) 2/15 (13)
Dysplasia 6/9 (67) 7/8 (88)3 1/6 (17) 8/12 (67)
CIS/LSCC 5/6 (83) 4/5 (80)3 4/5 (80) 4/7 (57)
1The positive group includes both lesions with scattered and those with complete positive nuclear
staining.–2Values are given in loss/informative cases (% loss).–3Including microsatellite instability in 1
lesion.
TABLE III – CORRELATION BETWEEN ISH PATTERN, LOH DATA AND p53 STATUS
ISH chromosomal pattern1
Chromosomal locus p53 IHC positive
staining29p21 17p13 18q21
Overall disomy 0/63 (0) 0/7 (0) 0/5 (0) 0/9 (0)
Sole trisomy 7 4/6 (67) 3/54 (60) 0/2 (0) 2/7 (29)
Overall tetrasomy 7/7 (100) 4/4 (100) 0/4 (0) 6/9 (67)
Imbalances/polysomy5 4/6 (67) 5/6 (83) 5/7 (71) 6/8 (75)
1Chromosomal patterns based on ISH results of all 5 chromosomes tested.–2Positive group includes
both lesions with scattered and those with complete positive nuclear staining.–3Values are given in
loss/informative cases (% loss).–4Including microsatellite instability detected in 2 lesions.–5Chromosomal
copy number imbalances and/or polysomy, detected for at least 2 of the 5 chromosomes studied.
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observed, possibly representing a next step in the carcinogenic
process. In the majority of cases, however, both chromosomal
duplication and allelic loss were observed in the same region of a
biopsy specimen, often together with over-expression of the tu-
mor-suppressor gene p53, suggesting that although LOH of 9p21
and 17p13 occurs as a first change, this is followed by chromo-
somal duplication and alterations in the p53 gene.
How can LOH at 18q21 take place after tetraploidization? The
follow-up biopsies studied from case 16 illustrate that allelic loss
at this locus occurs after tetraploidization. It can be hypothesized
that the presence of chromosomal instability is essential for LOH
to take place in the later stages of tumorigenesis, when most
chromosomes are present in 4 copies. This instability appears to be
enhanced after tetraploidization and results in chromosomal gains
and losses.7,25 It remains to be determined whether there is com-
plete loss of 1 of the alleles on 18q21 or deletion of 1 of the 4
copies resulting in allelic imbalance. Chromosome 18 showed a
relative copy number loss in 2 of 3 invasive carcinomas, both of
which showed LOH at 18q21, suggesting that LOH at 18q21 is one
of the direct results of chromosome instability and that this allelic
loss may be important for malignant progression of laryngeal
lesions.
Our ISH analysis frequently detected small groups of cells with
chromosomal alterations, situated within lesions that showed an
overall disomic chromosomal pattern. In addition, in 2 cases (cases
17 and 18), genetic changes were observed in a hyperplastic region
but not in the dysplastic region located in the same biopsy. This
kind of disparity between genotype and phenotype has also been
witnessed by Mao et al.,26 studying LOH in advanced lesions of
the head and neck following chemoprevention therapy. These
observations underline the importance of ISH as a screening
method for the identification of the most altered (genetically) cell
population in a biopsy specimen. Small groups of cells can be
identified within a tissue section on the basis of a deviation in the
chromosomal content, microdissected and studied by PCR ampli-
fication. In this study, a minimum of approximately 1,000 nuclei
was required for microsatellite analysis. Use of a whole genome
amplification step before microsatellite analysis will most proba-
bly reduce the acquired number of cells to an amount where even
small groups of about 10 cells with a specific chromosomal content
can be studied for the presence of LOH.27,28 In addition, this will
allow the investigation of allelic loss at multiple loci. These
approaches may prove to be invaluable for the implementation of
microarray-based techniques in these research fields.
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